Biotechnology

Sanofi taps AI-native biotech expert Paulo Fontoura to lead its global R&D, a high-stakes move to accelerate drug discovery after recent pipeline disappointments.

A new partnership between Pirche and Natera promises to connect pre-transplant risk analysis with post-transplant monitoring, ushering in an era of truly personalized care.

A new index reveals pharma's $8B ad spend fails to buy AI visibility. Eli Lilly and Novo Nordisk lead as AI follows patient research, not TV spots.

With no approved drugs for the Bundibugyo Ebola outbreak, 101 Therapeutics releases un-reviewed data, forcing a global health showdown between speed and safety.

Straive's acquisition of NextGen Invent isn't just another deal; it's a strategic strike to dominate the AI operationalization market. Here's why.

At BIO 2026, Fapon Group unveils a novel strategy combining T-cell engagers and in vivo CAR-T to target complex diseases. What does this mean for the future?

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

As global supply chains shift, a conference in Montreal highlights a crucial trade realignment. But are Canadian firms ready to seize the massive EU opportunity?

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

Gary Clark dissects Avance Clinical's bold move into Asia's booming biotech hubs, revealing why the region is now essential for global drug development.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.

South Korean brand Lactomedi’s nationwide CVS launch signals a major shift in feminine care, blending K-Beauty innovation with advanced microbiome science.

South Korea's Wellness Innercell targets Indonesia's booming wellness market. Its Surabaya-first strategy reveals a calculated blueprint for navigating Southeast Asia.

A prestigious award for its ASD therapy Speragen puts Korean biotech Astrogen in the spotlight. Now, the firm faces the gauntlet of regulatory approval and market entry.

The biotech firm's revenue plummeted as losses soared. But behind the numbers is a calculated pivot to cancer therapy, fueled by a Nasdaq debut and new cash.

AbbVie's latest dividend increase isn't just good news for investors; it's a window into the pharma giant's strategy for navigating future challenges.

A scientific shift from replacement to regeneration is fueling a market set to surpass $100B. But can new players navigate the regulatory and commercial hurdles?

An independent study reveals a Quebec-based platform dramatically improves patient outcomes and slashes clinical workload. Is this the new OS for healthcare?

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.